Close Menu

Becton Dickinson

The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.

Test capacity, particularly for rapid antigen testing, is set to explode in Q1 2021, but home and asymptomatic assays remain few and far between.

News items for the in vitro diagnostics industry for the week of Nov. 23, 2020.

The FDA cleared a CellaVision test that provides differential counts of white blood cells, characterization of red blood cell morphology, and platelet estimations.

The deal comes one week after the Netherlands said it was buying 9.2 million of the tests. The Canadian government is also purchasing 2,172 BD Veritor Plus Systems.

According to some analysts, the selloff in IVD company shares may be an overreaction, and SARS-CoV-2-related testing will be needed for some time in the future. 

For the full year, the Franklin Lakes, New Jersey company saw a decline in revenues of 1 percent compared to 2019.

The order is the first from a European government following CE-IVD mark in September. The firm expects to ship 1.2 million of the assays by mid-November.

The firms previously received CE mark for a COVID-19 test on the BD Max system in March.

The BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes has been used for more than a decade to assess immune function in HIV patients.